by Truveta Research | Aug 23, 2024 | Research, Research Insights
Authors: Charlotte Baker DrPH MPH CPH ⊕Truveta, Inc, Bellevue, WA, Brianna M. Goodwin Cartwright ⊕Truveta, Inc, Bellevue, WA, Patricia J. Rodriguez, PhD MPH ⊕Truveta, Inc, Bellevue, WA, Samuel Gratzl PhD ⊕Truveta, Inc, Bellevue, WA, Nicholas Stucky, MD PhD ⊕Truveta,...
by Truveta staff | Sep 12, 2023 | News
Medical Components, Inc. and Truveta are partnering to advance the use of real-world data to improve clinical care for patients battling cancer and kidney disease who require advanced vascular access for treatment. Truveta delivers the most complete, timely, and clean...
by Truveta Research | Jul 10, 2023 | Research, Research Insights
We explored the demographic characteristics of patients with type 2 diabetes mellitus, heart failure, and chronic kidney disease who received a prescription for empagliflozin (Jardiance) and/or dapagliflozin (Farxiga), two commonly used SGLT2i drugs. We saw...
